Table 2.

Patient characteristics and adverse events after TCR gene–transduced lymphocyte transfer

MAGE-A4 expressionsPrevious therapy
CohortCell doses allocatedPatient IDAge/sexPCRaIHCb/57B AbIHCb/MCV-1 AbIHCb/MCV-4 AbSurgeryRadiotherapyChemotherapyTumor lesionsNumber of IFNγ+ CD8+ T-cell infusedAdverse events (grade)
12 × 108TCR-MA-10268/M2,880NA+CDDP/5-FULiver1.46 × 107None
2 × 108TCR-MA-10456/M4,84720%20%20%+CDDP/5-FUEsophagus1.24 × 107None
2 × 108TCR-MA-10673/M2,21510%05%+CDDP/5-FU, TS-1Esophagus, lymph node1.48 × 107Skin reaction(I)d
21 × 109TCR-MA-20867/M7,94230%90%10%+CDDP/5-FULymph nodec6.8 × 107None
1 × 109TCR-MA-20957/M1,35270%10%50%++CDDP/5-FULymph node1.3 × 108None
1 × 109TCR-MA-21054/M31230%20%20%CDDP/5-FU, DocetaxelEsophagus, lung, lymph node9.6 × 107Skin reaction(I)d
1 × 109TCR-MA-21243/M1,76520%10%5%++CDDP/5-FU, DocetaxelLymph nodec2.6 × 108Skin reaction(I)d
35 × 109TCR-MA-21368/M749NA++CDDP/5-FULymph nodec5.3 × 108None
5 × 109TCR-MA-31464/M82FocalFocalFocal++CDDP/5-FULymph node6.6 × 108None
5 × 109TCR-MA-31557/FNA20%20%20%++CDDP/5-FULung, lymph node9.75 × 108Skin reaction(I)d

Abbreviations: NA, not available; 5-FU, 5-fluorouracil; CDDP, cisplatin.

  • aCopy numbers amplified by real-time PCR.

  • bPositive percentage in tumor samples by IHC staining.

  • cMinimal lesions, unable to evaluate by RECIST.

  • dSkin reactions were related to peptide vaccinations.